The term ''Non-invasive ventilation'' (NIV) refers to various methods of respiratory assistance, in the absence of an indwelling endotracheal tube. In recent years, the use of NIV has increased for the treatment of both acute and chronic pediatric respiratory failure. Patient tolerance to the technique is a critical factor determining its success in avoiding endotracheal intubation. One of the key factors determining tolerance to NIV is optimal synchrony between the patient's spontaneous breathing activity and the ventilator's set parameters, known as ''patient-ventilator interaction''.
Indeed, synchronization of the ventilator breath with the patient's inspiratory effort, optimizes comfort, minimizes work of breathing and reduces the need for sedation. During NIV, several factors can significantly interfere with the function of the ventilator, leading to an increased risk of asynchrony. Indeed, the presence of unintentional leaks at the patient-mask interface, the sensitivity of inspiratory and expiratory triggers, the ability to compensate for intentional and unintentional leaks and the presence/absence of expiratory valves are all factors that likely play a role in determining patient-ventilator synchronization.
The investigators therefore designed the present crossover trial in order to compare the degree of respiratory asynchronies during NIV using different ventilators (Turbine-driven ventilator vs. compressed air-driven ICU ventilators) and different setups (single circuit vs. double circuit) in children with acute respiratory failure.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pediatric Respiratory Diseases | Device: Single-Limb Turbine-Driven Ventilator Device: Double-Limb Intensive Care Unit ventilator Device: Double-Limb Turbine-Driven Ventilator | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Outcomes Assessor) |
Masking Description: | Analysis of respiratory tracings will be blinded to the type of respiratory support. |
Primary Purpose: | Treatment |
Official Title: | Role of Type of Respiratory Circuit and Type of Ventilator on Asynchronies During Non-invasive Ventilation (NIV) in Children With Acute Respiratory Failure: an Interventional, Nonpharmacological Crossover Study |
Actual Study Start Date : | September 15, 2019 |
Estimated Primary Completion Date : | July 15, 2021 |
Estimated Study Completion Date : | July 15, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Single-limb circuit with turbine-driven ventilator
Non invasive ventilation delivered with a turbine-driven ventilator, single limb with intentional leaks.
|
Device: Single-Limb Turbine-Driven Ventilator
Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
|
Experimental: Double-limb circuit with Intensive Care Unit ventilator
Non invasive ventilation delivered with an intensive care unit ventilator with a double limb circuit.
|
Device: Double-Limb Intensive Care Unit ventilator
Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
|
Experimental: Double-limb circuit with turbine-driven ventilator
Non invasive ventilation delivered with a turbine-driven ventilator with a double limb circuit.
|
Device: Double-Limb Turbine-Driven Ventilator
Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
|
Ages Eligible for Study: | 1 Month to 4 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Thomas Langer, MD | +39-2-55032242 | thomas.langer@unimi.it | |
Contact: Giovanna Chidini, MD | +39-2-55032242 | giovanna.chidini@policlinico.mi.it |
Italy | |
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Recruiting |
Milano, Italy, 20122 | |
Contact: Thomas Langer 0255033232 | |
Contact: Giovanna Chidini | |
Sub-Investigator: Cristina Villa, MD | |
Sub-Investigator: Giulia Spolidoro, MD | |
Sub-Investigator: Veronica Doria, MD | |
Sub-Investigator: Edi Prandi, MD |
Study Chair: | Edoardo Calderini, MD | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 10, 2019 | ||||||||
First Posted Date ICMJE | July 12, 2019 | ||||||||
Last Update Posted Date | November 27, 2019 | ||||||||
Actual Study Start Date ICMJE | September 15, 2019 | ||||||||
Estimated Primary Completion Date | July 15, 2021 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Asynchrony Index [ Time Frame: 90 minutes ] Difference in Asynchrony index [expressed as percentage] between different modalities of Non-invasive ventilation.
|
||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Asynchronies in Pediatric Noninvasive Ventilation | ||||||||
Official Title ICMJE | Role of Type of Respiratory Circuit and Type of Ventilator on Asynchronies During Non-invasive Ventilation (NIV) in Children With Acute Respiratory Failure: an Interventional, Nonpharmacological Crossover Study | ||||||||
Brief Summary |
The term ''Non-invasive ventilation'' (NIV) refers to various methods of respiratory assistance, in the absence of an indwelling endotracheal tube. In recent years, the use of NIV has increased for the treatment of both acute and chronic pediatric respiratory failure. Patient tolerance to the technique is a critical factor determining its success in avoiding endotracheal intubation. One of the key factors determining tolerance to NIV is optimal synchrony between the patient's spontaneous breathing activity and the ventilator's set parameters, known as ''patient-ventilator interaction''. Indeed, synchronization of the ventilator breath with the patient's inspiratory effort, optimizes comfort, minimizes work of breathing and reduces the need for sedation. During NIV, several factors can significantly interfere with the function of the ventilator, leading to an increased risk of asynchrony. Indeed, the presence of unintentional leaks at the patient-mask interface, the sensitivity of inspiratory and expiratory triggers, the ability to compensate for intentional and unintentional leaks and the presence/absence of expiratory valves are all factors that likely play a role in determining patient-ventilator synchronization. The investigators therefore designed the present crossover trial in order to compare the degree of respiratory asynchronies during NIV using different ventilators (Turbine-driven ventilator vs. compressed air-driven ICU ventilators) and different setups (single circuit vs. double circuit) in children with acute respiratory failure. |
||||||||
Detailed Description |
After having obtained the signed informed consent from the parents of the patient, a 6 Fr pediatric esophageal balloon-catheter will be placed through a nostril in the distal third of the esophagus. This minimally invasive procedure, will allow to monitor and record esophageal pressure swings, which are strongly correlated to pleural pressure variations and therefore allow to detect accurately patients' inspiratory efforts. Furthermore, surface electrodes will be placed in order to record the electrical activity of the diaphragm non-invasively. In every patient, three breathing trials (30 minutes each) will be performed in randomized order:
The NIV setting decided clinically will not be modified for the study and will be held constant throughout the different study phases. Similarly, if sedative drugs are being delivered to the patient, the attending physician will decide their dose and it will be kept constant throughout the study phases. The Comfort scale will be assessed for each study phase, in order to evaluate and describe the comfort/distress of the patients during the different ventilatory strategies. Esophageal pressure tracings, inspiratory/expiratory air flows, airway pressure measured at the patient-ventilator interface and electrical activity of the diaphragm (measured with surface electrodes) will be continuously recorded with a dedicated software throughout the study in order to compute, offline, the asynchrony index (see below). Asynchronies will be defined according to previous studies on the subject:
The entity of asynchronies can be numerical summarized in the Asynchrony Index (AI), which is calculated as the total number of asynchrony events divided by the total number of non-triggered and triggered ventilatory cycles (expressed as percentage). Asynchrony Index (%) = [(AT + IE + LC + PC + DT) / (RRpes + AT)]×100 Where AT refers to Auto-triggering, IE to ineffective triggering, LC to late cycling, PC to premature cycling, DT to double triggering and RRpes to the respiratory rate as measured using the esophageal pressure tracing. Furthermore, the number of each type of asynchrony will be assessed (number of events per minute), in order to identify the most relevant types of asynchronies. Randomization The randomization of the three NIV-phases will be performed with an online randomization software called "Research Randomizer" (https://www.randomizer.org). No risk of bias is foreseen, as all patients will undergo the three interventions (cross-over study). Blinding. The respiratory traces registered during the different study phases and analyzed offline in order compute the "Asynchrony Index" will be evaluated by an investigator blinded to the type of intervention. PRIMARY ENDPOINT Primary endpoint of the present study is the difference in Asynchrony Index (expressed as %) obtained during NIV performed with an ICU ventilator using a double limb circuit and the value obtained during NIV performed with single limb circuit with intentional leak with a turbine-driven ventilator. Secondary endpoint Secondary endpoint of the present study is the difference in Asynchrony Index (expressed as %) obtained during NIV performed with an ICU ventilator using a double limb circuit and the value obtained with the same type of circuit, but with a turbine-driven ventilator. STATISTICAL ANALYSIS Sample size calculation. The sample size for the primary endpoint of the study has been calculated using the software G*Power 3.1.9.2 using a paired t-test and using as outcome parameter the difference in Asynchrony Index (AI) during NIV performed with ICU ventilators and with turbine-driven ventilators applied with single limb circuit and intentional leaks. Based on available data the investigators estimated in our population an AI of 59±13% and considered a 20% reduction of its value as clinically relevant (AI=47±13%). Considering a two-tailed alfa error of 0.05 and a desired power of 0.8, with an effect size of 0.923 the investigators calculated a sample size of 12 patients. DATA ANALYSIS All data will be tested for homogeneity of variance and normality of distribution using the Shapiro- Wilk test. Normally distributed data will be expressed as mean ± standard deviation, while nonnormally distributed data as median and interquartile range. The presence of outliers will be carefully assessed during evaluation of distribution of data; however, no action is foreseen to exclude outliers. Variables (Asynchrony Index, respiratory rate, tidal volume, minute ventilation, esophageal pressure variation, etc.) recorded during the different NIV modalities will be compared via paired t-test or Signed Rank Sum test, as appropriate. Mean difference and its 95% CI will be calculated for normally distributed data. For non-normally distributed variables, median difference and its 95% CI will be estimated by Hodges-Lehmann's median analysis. All tests will be two tailed and statistical significance is defined as p<0.050. Analysis will be performed with SigmaPlot v.12.0 (Systat Software Inc., San Jose, CA) and SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Of note, the above-noted statistical procedures are appropriate but will not exclude other procedures that may also be used in addition to or in lieu of the stated procedures in order to best analyze the data. No control subjects will be needed, as each patient will serve as its own control for the subsequent measurements (cross-over study). |
||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Not Applicable | ||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single (Outcomes Assessor) Masking Description: Analysis of respiratory tracings will be blinded to the type of respiratory support. Primary Purpose: Treatment
|
||||||||
Condition ICMJE | Pediatric Respiratory Diseases | ||||||||
Intervention ICMJE |
|
||||||||
Study Arms ICMJE |
|
||||||||
Publications * |
|
||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
12 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date ICMJE | July 15, 2021 | ||||||||
Estimated Primary Completion Date | July 15, 2021 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 1 Month to 4 Years (Child) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | Italy | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT04017780 | ||||||||
Other Study ID Numbers ICMJE | ASYN-VENT | ||||||||
Has Data Monitoring Committee | No | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Responsible Party | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | ||||||||
Study Sponsor ICMJE | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | ||||||||
Collaborators ICMJE | Not Provided | ||||||||
Investigators ICMJE |
|
||||||||
PRS Account | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | ||||||||
Verification Date | November 2019 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |